Clinical trial Recruiting at 1 site Observational Ages 18 and up

Factors Linked to Worsening or Improving Knee Osteoarthritis Over Time in Early Knee OA or Prior Acute Knee Injury

Official title: Imperial Knee Health Cohort: New Exploration of Early-stage Changes Study.

Run by Imperial College London · NCT07833488 · Data updated 2026-11-12

This observational study follows adults with early knee osteoarthritis or a prior knee injury to see if certain blood or knee-fluid markers, or genetic factors, can predict whether their knee condition will get worse or improve.

More Knee Osteoarthritis trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment200 (estimated)
SponsorImperial College London
Academic / other
Drugs / interventionschemotherapy
Locations1 site (London)
StatusRecruiting
StartedSeptember 14, 2026
Main results expectedJuly 31, 2031
Study endsJuly 31, 2031
Registry record updatedNovember 6, 2026
Trial IDNCT07833488 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 and older with early-stage knee OA, a history of acute traumatic knee injury (≤50 for those with prior injury), or a symptomatic degenerative meniscal tear.

Probably not a fit

People without early knee OA, without prior knee injury, or without detectable biomarkers may be less likely to benefit from insights gained.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This non-interventional cohort study recruits adults 18 years and older with early knee OA, a history of acute knee injury, or a degenerative meniscal tear. Participants provide samples such as blood, cheek swabs, and knee fluid when they are already undergoing routine care or procedures. Researchers will analyze these samples for biological markers and genetic factors to see how they relate to future changes in knee symptoms and structure. The study aims to improve understanding of why OA progresses in some people and remains stable in others, potentially guiding future predictions and personalized care.

Why it matters

Potential benefit: If successful, the study could help clinicians predict which patients are more likely to experience worsening or stabilization of knee OA.

How similar studies have gone: Similar biomarker and genetic studies in OA have provided useful correlations, but predictive power remains an active area of research.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

ALL participants must meet the following criteria:

* Male or female, aged ≥18 years of age AND at least one of the following (a-d):

  1. A definite diagnosis of knee osteoarthritis , evidenced by consistent knee symptoms and imaging findings, commensurate with non-advanced KL grade changes (KL 0-2 where an X-ray grade is available)
  2. A symptomatic degenerative meniscal tear with or without definite imaging findings suggesting knee osteoarthritis
  3. Probable early-stage symptomatic knee osteoarthritis without definite imaging changes, fulfilling NICE diagnostic criteria for osteoarthritis:

     * Age 45 or over
     * Activity-related knee pain.
     * Either no morning stiffness or that lasts \<30 minutes
  4. A definite clinically significant acute knee injury at the age of 50 or younger at any stage in the past, evidenced by appropriate clinical history of a traumatic knee episode AND documented imaging or surgical confirmation of a relevant structural injury.
* Willing to provide at least one of the following samples: synovial fluid or blood (a salivary sample is an acceptable alternative for remote participants with a history of knee injury. This alternative also applies to existing participants from ICHTB/IHKB, for whom no prior DNA sample is currently banked)
* Understand English sufficiently to be able to read PIS, ICF and/or Participant Invitation Letter
* Provide an ICF, signed by the participant
* Be capable of complying with Protocol requirements, i.e. completing study questionnaire packs.

Exclusion Criteria:

* Known advanced radiographic changes of KOA on available imaging (KL grade 3-4 where available), or other commensurate findings, such as those present on MRI
* Knee joint replacement (uni-compartmental arthroplasty or total knee arthroplasty) of the index knee, prior to consent, or planned during current episode of care, or within next 12 months
* Other clinically significant knee pathology such as infection or malignancy affecting the index knee joint or surrounding bone (at any time)
* Surgery to the index knee in the last 3 months
* Any other systemic inflammatory disease (e.g. inflammatory bowel disease), systemic infection, or inflammatory arthritis (e.g. rheumatoid arthritis, psoriatic arthritis, gout)
* Systemic/intra-articular steroid use to index knee in the last 3 months
* Any use of immunosuppressive drugs or chemotherapy in the last 12 months
* Unwilling or unable to provide follow-up data for minimum 2 years and/or maximum 5 years
* Pregnancy, expecting to be pregnant, near the scheduled Year 2 or Year 3 X-ray visit.
* Other medical reason which would prevent participation, at the discretion of the investigator.

Where it's running

  • Centre for Inflammatory Disease, 9th Floor, Commonwealth Building, Imperial College London, Department of Immunology and Inflammation, Hammersmith Campus, Du Cane Road, London
    London, United Kingdom
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.